お知らせ • Mar 10
Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026 Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026, at 09:00 China Standard Time. Location: 7/f, china united plaza, 1002-1008, tai nan west street, cheung sha wan, kowloon Hong Kong Reported Earnings • Feb 01
Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024) Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024). お知らせ • Jan 10
Ping An Biomedical Co., Ltd. announced a financing transaction Ping An Biomedical Co., Ltd. entered into a Securities Purchase Agreement and announced a private placement January 9, 2026. The transaction involves participation from individual investors Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor. New Risk • Jan 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Minor Risks Market cap is less than US$100m (US$12.7m market cap). New Risk • Nov 26
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.56m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Market cap is less than US$10m (US$9.56m market cap). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Board Change • Nov 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jifeng Gao is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 05
First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024) First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024). Buy Or Sell Opportunity • Oct 01
Now 23% undervalued The stock has been flat over the last 90 days, currently trading at US$0.98. The fair value is estimated to be US$1.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Sep 05
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at US$1.08. The fair value is estimated to be US$1.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making. Board Change • Aug 12
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Aug 06
Now 27% overvalued The stock has been flat over the last 90 days, currently trading at US$1.75. The fair value is estimated to be US$1.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making. お知らせ • Jul 18
Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million. Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,500,000
Price\Range: $6
Discount Per Security: $0.42 Board Change • Jul 18
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.